Stock analysts at Seaport Global Securities assumed coverage on shares of BeyondSpring (NASDAQ:BYSI) in a report issued on Tuesday, reports. The brokerage set a “buy” rating and a $56.00 price target on the stock. Seaport Global Securities’ price objective would indicate a potential upside of 72.25% from the stock’s current price.

BYSI has been the subject of a number of other reports. Maxim Group reaffirmed a “buy” rating and set a $52.00 price target on shares of BeyondSpring in a research note on Friday, October 27th. Zacks Investment Research downgraded BeyondSpring from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. Finally, HC Wainwright set a $60.00 price target on BeyondSpring and gave the stock a “buy” rating in a research note on Thursday, October 26th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. BeyondSpring currently has a consensus rating of “Buy” and an average target price of $54.50.

BeyondSpring (NASDAQ BYSI) traded down $1.30 on Tuesday, hitting $32.51. The stock had a trading volume of 400 shares, compared to its average volume of 5,475. BeyondSpring has a 52 week low of $16.55 and a 52 week high of $48.49.

BeyondSpring (NASDAQ:BYSI) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.01. equities research analysts anticipate that BeyondSpring will post -4.41 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in BeyondSpring stock. Tanaka Capital Management Inc. acquired a new stake in BeyondSpring Inc. (NASDAQ:BYSI) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring makes up 2.1% of Tanaka Capital Management Inc.’s portfolio, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring at the end of the most recent reporting period. Institutional investors and hedge funds own 1.22% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “BeyondSpring (BYSI) Earns Buy Rating from Analysts at Seaport Global Securities” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at

About BeyondSpring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with's FREE daily email newsletter.